In March, the Food and Drug Administration announced an important milestone in the fight against Rett syndrome. The FDA approved Daybue (trofinetide), a prescription oral treatment for adults and children 2 years of age and older who suffer from this rare but devastating neurological disorder. The development and approval of the first official treatment for Read more…
